Colin Goddard

About

Colin Goddard joined Coferon as part-time Executive Chairman in 2011 and assumed the Chairman and CEO roles following the Series B financing in July 2012. From October 1998, until its $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc., a company he joined as a scientist in 1989. During his tenure as CEO, Dr. Goddard presided over the transition of OSI from a technology platform based drug discovery company into a premier, highly profitable and fully integrated biopharmaceutical organization - completing multiple major acquisitions and divestitures and raising over $1.5 billion in capital. He is also Chairman of the start-up Biotech company Mergenser, a Director of the Biotechnology companies Human Genome Sciences, Inc, Agendia and PanOptica, Inc., and sits on the Oncology advisory board for Glaxo Smith Kline. Dr. Goddard has been active in many organizations that promote the advancement of cancer treatment and

Investment Focus

Location

West Palm Beach, US